STOCK TITAN

30,803 options granted to FibroBiologics (FBLG) director Olivia

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FibroBiologics, Inc. director Niklas Victoria Ninon Olivia received a grant of 30,803 stock options to buy common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of grant or the next annual meeting and expire on June 22, 2036. Following this award, Olivia directly holds 30,803 options.

Positive

  • None.

Negative

  • None.
Insider Niklas Victoria Ninon Olivia
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 30,803 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 30,803 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 30,803 options Stock Option (Right to Buy) granted to director
Exercise price $0.7503 per share Exercise price for underlying common stock
Underlying shares 30,803 shares Common stock underlying the options
Post-transaction options held 30,803 options Total options directly held after the grant
Expiration date June 22, 2036 Option expiration for this award
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) linked to common stock"
exercise price financial
"conversion_or_exercise_price: 0.7503 per underlying common share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vesting financial
"The options will vest in full upon the earlier of the first anniversary or next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting financial
"vest in full upon the earlier of the first anniversary or the date of the next annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did FibroBiologics (FBLG) report for Niklas Olivia?

FibroBiologics reported that director Niklas Victoria Ninon Olivia received a grant of 30,803 stock options. These options give the right to buy common stock at an exercise price of $0.7503 per share, with vesting tied to time or the next annual meeting.

What are the key terms of the 30,803 stock options granted at FibroBiologics (FBLG)?

The grant covers 30,803 stock options on FibroBiologics common stock with an exercise price of $0.7503 per share. The options expire on June 22, 2036, providing a long-dated incentive tied to the company’s equity performance over time.

When do Niklas Olivia’s FibroBiologics (FBLG) options vest?

The options will vest in full on the earlier of two events: the first anniversary of the grant date or the date of FibroBiologics’ next annual meeting. This time-based vesting encourages continued board service through at least one full annual meeting cycle.

How many FibroBiologics (FBLG) options does Niklas Olivia hold after this grant?

After the reported transaction, Niklas Victoria Ninon Olivia directly holds 30,803 stock options. This total matches the size of the new award, indicating these are the options shown as outstanding for Olivia in this particular insider report.

Is the FibroBiologics (FBLG) transaction a purchase or a grant of options?

The transaction is a grant or award of stock options, not an open-market purchase. Classified under code “A,” it reflects compensation-related acquisition of derivative securities, giving Olivia the right to buy shares later at a fixed exercise price.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Niklas Victoria Ninon Olivia

(Last)(First)(Middle)
C/O FIBROBIOLOGICS, INC.
9350 KIRBY DRIVE., SUITE 300

(Street)
HOUSTON, TEXAS 77054

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.750306/23/2026A30,803 (1)06/22/2036Common Stock30,803$030,803D
Explanation of Responses:
1. The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
/s/ Ruben A. Garcia, by Power of Attorney06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)